Grifols, ES0171996087

Grifols stock: At EUR 10.01, Grifols stock trades 1.67 percent below the BME close

Published on 10/19/2026 at 16:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Almirall has a P/E of 30.09 versus 14.93 for Grifols. Grifols stock costs EUR 10.01 on October 19, 2026, down 1.67 percent versus the BME close.

Price position and valuation

The BME session put Grifols 1.67 percent below its October 16, 2026 close.
Almirall trades at a P/E of 30.09, versus 14.93 for Grifols on October 19, 2026.
Grifols stock costs EUR 10.01 at Lang & Schwarz on October 19, 2026 at 4:34 p.m. CEST, 1.67 percent below the BME close of October 16, 2026.
Grifols has a market capitalization of EUR 6.1 billion.

Fotorealistische Plasma-Fraktionierungsanlage, Biotech-Produktion, unbeschriftete Industriehalle — Fotorealistische Ansicht einer Plasma-Fraktionierungsanlage zeigt Grifols S.A. ES0171996087 in moderner Biotech-Produktion mit Reinraumtechnik, Illustration mit AI erstellt.

Grifols (ISIN ES0171996087) traded at EUR 10.01 at Lang & Schwarz on October 19, 2026 at 4:34 p.m. CEST, down 1.67 percent from the BME close of October 16, 2026. The move places the stock below its most recent completed Spanish session as European trading progressed.

Grifols stock was valued at a P/E ratio of 14.93, while Almirall stood at 30.09 on October 19, 2026. The comparison points to a lower earnings multiple for Grifols than one Spanish healthcare peer, although the companies have different product portfolios and financial profiles.

Price levels define the session

The intraday quote included a bid of EUR 10.00 and an ask of EUR 10.02 at Lang & Schwarz. The spread was EUR 0.02, giving investors a narrow indication around the EUR 10.01 trading level.

Grifols remained below the BME close of EUR 10.18 from October 16, 2026. The company is valued at EUR 6.1 billion, while its Nasdaq-listed American depositary shares had a market capitalization of USD 6.4 billion in the latest finance snapshot used for the U.S. listing.

Valuation differs across healthcare peers

Almirall traded at EUR 9.97 on October 19, 2026, down 0.50 percent from its prior close, with a P/E of 30.09 and a market capitalization of EUR 2.2 billion. Pharma Mar traded at EUR 67.80, down 0.15 percent, with a P/E of 20.78 and a market capitalization of EUR 1.2 billion.

Comparison with peers

Grifols (BME, EUR): minus 1.67 percent, P/E 14.93, market capitalization EUR 6.1 billion

Almirall (BME, EUR): minus 0.50 percent, P/E 30.09, market capitalization EUR 2.2 billion

Pharma Mar (BME, EUR): minus 0.15 percent, P/E 20.78, market capitalization EUR 1.2 billion

Trading remains below the close

The price position is the clearest market signal for Grifols on October 19, 2026. The stock traded EUR 0.17 below the BME close, while the peer comparison showed a larger daily decline for Grifols than for Almirall or Pharma Mar.

Grifols was trading at EUR 10.01 at Lang & Schwarz on October 19, 2026 at 4:34 p.m. CEST, 1.67 percent below the BME close of October 16, 2026. The further course of trading is shown by the continuously updated real-time quote of Grifols stock.